HK1049441A1 - 普伐他丁鈉的嶄新形式 - Google Patents

普伐他丁鈉的嶄新形式

Info

Publication number
HK1049441A1
HK1049441A1 HK03101565.0A HK03101565A HK1049441A1 HK 1049441 A1 HK1049441 A1 HK 1049441A1 HK 03101565 A HK03101565 A HK 03101565A HK 1049441 A1 HK1049441 A1 HK 1049441A1
Authority
HK
Hong Kong
Prior art keywords
pravastatin sodium
novel forms
novel
forms
pravastatin
Prior art date
Application number
HK03101565.0A
Other languages
English (en)
Inventor
Keri Vilmos
Szabo Csaba
Nagyne Arvai Edit
Aronhime Judith
Original Assignee
Biogal Gyogyszergyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26866349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1049441(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar
Publication of HK1049441A1 publication Critical patent/HK1049441A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/48Separation; Purification; Stabilisation; Use of additives
    • C07C67/52Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/26All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03101565.0A 1999-12-14 2003-03-03 普伐他丁鈉的嶄新形式 HK1049441A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17068599P 1999-12-14 1999-12-14
US19064900P 2000-03-20 2000-03-20
PCT/US2000/033867 WO2001043723A1 (en) 1999-12-14 2000-12-14 Novel forms of pravastatin sodium

Publications (1)

Publication Number Publication Date
HK1049441A1 true HK1049441A1 (zh) 2003-05-16

Family

ID=26866349

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101565.0A HK1049441A1 (zh) 1999-12-14 2003-03-03 普伐他丁鈉的嶄新形式

Country Status (15)

Country Link
US (3) US7001919B2 (zh)
EP (1) EP1242051A4 (zh)
JP (2) JP2003516959A (zh)
KR (1) KR20020062340A (zh)
CN (1) CN1434702A (zh)
AU (1) AU779306B2 (zh)
CA (1) CA2394200C (zh)
CZ (1) CZ20021998A3 (zh)
HK (1) HK1049441A1 (zh)
HU (1) HUP0204005A3 (zh)
IL (1) IL150187A0 (zh)
PL (1) PL364929A1 (zh)
SK (1) SK8312002A3 (zh)
WO (1) WO2001043723A1 (zh)
YU (1) YU45202A (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2394200C (en) * 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
ES2292721T3 (es) * 2001-03-27 2008-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivado de isoxazol cristalino y preparacion medica del mismo.
US20080242725A1 (en) * 2004-03-01 2008-10-02 Janez Kerc Pharmaceutical Composition
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
WO2006086680A1 (en) * 2005-02-09 2006-08-17 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Methods of making pravastatin sodium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
WO2012085191A1 (en) 2010-12-23 2012-06-28 Dsm Sinochem Pharmaceuticals Netherlands B.V. Crystalline form of pravastatine and process for the preparation thereof
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
CN105949062B (zh) * 2016-06-24 2017-06-13 广东蓝宝制药有限公司 一种规模化制备普伐他汀钠d型晶体的工艺
CN111018714B (zh) * 2019-12-27 2020-09-04 广东蓝宝制药有限公司 一种获得高纯a晶型普伐他汀钠的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
EP0215665B1 (en) 1985-09-13 1991-11-21 Sankyo Company Limited Hydroxy-ml-236b derivatives, their preparation and use
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857522A (en) 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
NZ250609A (en) 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
WO1998037220A1 (en) 1997-02-20 1998-08-27 Dsm N.V. Nitrogen feed in statin fermentation
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
WO1999010499A1 (en) 1997-08-22 1999-03-04 Dsm N.V. Statin production by fermentation
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
WO2000033821A1 (en) * 1998-12-07 2000-06-15 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
CN1260344C (zh) 1999-02-03 2006-06-21 药物研究所有限公司 培养物
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
EP1265604B1 (en) 1999-11-30 2006-10-18 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
CA2394200C (en) * 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
JP3737801B2 (ja) 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
DE10209305A1 (de) 2001-04-30 2002-10-31 Basf Ag Thermische Spaltung von Allophanaten

Also Published As

Publication number Publication date
AU779306B2 (en) 2005-01-13
WO2001043723A1 (en) 2001-06-21
US7262218B2 (en) 2007-08-28
KR20020062340A (ko) 2002-07-25
HUP0204005A2 (hu) 2003-03-28
EP1242051A1 (en) 2002-09-25
CA2394200C (en) 2006-10-03
PL364929A1 (en) 2004-12-27
YU45202A (sh) 2005-11-28
CN1434702A (zh) 2003-08-06
US20050288370A1 (en) 2005-12-29
JP2003516959A (ja) 2003-05-20
EP1242051A4 (en) 2004-05-12
CZ20021998A3 (cs) 2003-02-12
IL150187A0 (en) 2002-12-01
AU2098701A (en) 2001-06-25
JP2005120105A (ja) 2005-05-12
CA2394200A1 (en) 2001-06-21
US20070197633A1 (en) 2007-08-23
SK8312002A3 (en) 2003-05-02
US20010041809A1 (en) 2001-11-15
HUP0204005A3 (en) 2003-05-28
US7001919B2 (en) 2006-02-21

Similar Documents

Publication Publication Date Title
IL159861A0 (en) Crystalline forms of fluvastatin sodium
HUP0202536A3 (en) Crystals of the sodium salt of pravastatin
IL150187A0 (en) Novel forms of pravastatin sodium
EG22530A (en) Preparation of substituted piperidin-4-ones
AU5586100A (en) Efficient synthesis of alkyl carbonates
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
HUP9902855A3 (en) Preparation of sterol- and stanol-esters
PL350963A1 (en) Use of arylalkanoylpyridazines
ZA200204500B (en) Forms of pravastatin sodium.
PL337598A1 (en) Novel compound - derivative of (r)-3-hydroxynonanal
TW406777U (en) Structure of lighting set
TW422400U (en) Improvement of transformer
TW468411U (en) Structure of cardcase
TW394123U (en) Structure of emery-roller
TW414292U (en) Improved structure of lantern
TW428758U (en) Improvement of counter
TW371057U (en) Structure of single lens
TW412058U (en) Structure of bulb fixed-cover
TW402874U (en) Improvement of shoes structure
TW399438U (en) Improved structure of bedhead
TW427109U (en) Improved structure of water lamp
HU9900075V0 (en) Sepulchre consists of elements
TW386360U (en) Improvement of underwear